David Michonneau
Overview
Explore the profile of David Michonneau including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
86
Citations
1083
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Le Grand S, Villemonteix J, Daguindau E, Fort M, Caillat-Zucman S, Allain V, et al.
Hemasphere
. 2025 Feb;
9(2):e70088.
PMID: 39949376
Donor lymphocyte infusion (DLI) prevents acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) relapses following hematopoietic stem cell transplantation. Given the life-threatening toxicities such as graft versus host disease (GVHD),...
2.
Divoux M, Resche-Rigon M, Michonneau D, Sutra Del Galy A, Dhedin N, Xhaard A, et al.
Am J Hematol
. 2024 Dec;
100(2):330-333.
PMID: 39629866
No abstract available.
3.
DeFilipp Z, Fox L, Holderried T, Mehra V, Michonneau D, Pashley A, et al.
Transplant Cell Ther
. 2024 Nov;
31(2):76.e1-76.e13.
PMID: 39536878
The objective of this meta-analysis (MA) was to evaluate the efficacy and safety of extracorporeal photopheresis (ECP) for the treatment of steroid-refractory chronic graft-versus-host disease (SR-cGvHD). A systematic literature review...
4.
Lambert N, Forte F, Moussaoui M, Monseur J, Raus N, Polushin A, et al.
Brain
. 2024 Oct;
PMID: 39442000
Despite the growing evidence supporting the existence of CNS involvement in acute and chronic graft-versus-host disease (CNS-GvHD), the characteristics and course of the disease are still largely unknown. In this...
5.
Bordenave J, Gajda D, Michonneau D, Vallet N, Chevalier M, Clappier E, et al.
J Clin Invest
. 2024 Aug;
134(20).
PMID: 39207851
BACKGROUNDDonor cell engraftment is a prerequisite of successful allogeneic hematopoietic stem cell transplantation. Based on peripheral blood analyses, it is characterized by early myeloid recovery and T and B cell...
6.
Kaphan E, Bettega F, Vallet N, Fegueux N, Robin M, Bazarbachi A, et al.
Haematologica
. 2024 Jun;
109(10):3373-3378.
PMID: 38867585
No abstract available.
7.
Michonneau D, Devillier R, Keranen M, Rubio M, Nicklasson M, Labussiere-Wallet H, et al.
Hematol Rep
. 2024 May;
16(2):283-294.
PMID: 38804281
Acute graft-versus-host disease (aGVHD) remains a barrier to successful allogeneic hematopoietic stem cell transplantation (HSCT) outcomes. Contemporary comprehensive analyses of real-world clinical outcomes among patients who develop aGVHD post-HSCT are...
8.
Xhaard A, Floch A, Ruggiu M, Robin M, Sicre de Fontbrune F, Michonneau D, et al.
Bone Marrow Transplant
. 2024 May;
59(9):1232-1238.
PMID: 38796632
In the case of donor/recipient rhesus (Rh)-incompatibility after allogeneic hematopoietic stem cell transplantation (alloHSCT), the transfusion policy in France is to transfuse red blood cells (RBC) in the donor's Rh...
9.
Robin M, Nibourel O, Tournaire M, Michonneau D, Preudhomme C, Verbanck M, et al.
Bone Marrow Transplant
. 2024 May;
59(9):1309-1312.
PMID: 38783124
No abstract available.
10.
Grimaud Y, Sicre de Fontbrune F, Michonneau D, Desnoyer A, Peffault de Latour R, Larghero J, et al.
Bone Marrow Transplant
. 2024 Feb;
59(5):711-713.
PMID: 38418622
No abstract available.